Skip to main content
Investors
Media
open in a new window
Contact Us
open in a new window
|
Search
open in a new window
Company
Science & Medicine
Patients
Responsibility
Careers
IR Home
Why Invest
Events & Presentations
Corporate Governance
Governance Documents
Executive Management
Board of Directors
Committee Composition
Contact the Board
Financials
Quarterly Results
Annual Reports
SEC Filings
Investor FAQs
Press Releases
Investor Contacts
Investor Emails Alerts
RSS Feeds
IR Home
Why Invest
Events & Presentations
Corporate Governance
Governance Documents
Executive Management
Board of Directors
Committee Composition
Contact the Board
Financials
Quarterly Results
Annual Reports
SEC Filings
Investor FAQs
Press Releases
Investor Contacts
Investor Emails Alerts
RSS Feeds
Close
Close
Investors
Company
Product
Research & Development
Patients
Partnerships
Careers
Close
Press Releases
Normal
Press Release RSS Feed (opens in new window)
Press release year list
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
December 1, 2021
Ironwood Pharmaceuticals Appoints Sravan K. Emany as Chief Financial Officer
November 4, 2021
Ironwood Pharmaceuticals Reports Third Quarter 2021 Results and Provides Corporate Development Update
November 4, 2021
Ironwood Pharmaceuticals Expands Pipeline by Signing an Option Agreement to Acquire an Exclusive License with COUR Pharmaceuticals to Develop and Commercialize CNP-104 for the Treatment of Primary Biliary Cholangitis (PBC) in the U.S.
October 25, 2021
More than 90% of Surveyed IBS-C Patients Who Had an ER Visit or Hospitalization in the Past Year Identified Abdominal Pain as a Symptom That Led to the Visit, According to Data Announced by Ironwood Pharmaceuticals at ACG 2021
October 21, 2021
Ironwood Pharmaceuticals to Host Third Quarter 2021 Investor Update Call
September 2, 2021
Ironwood Pharmaceuticals to Participate in Upcoming September Investor Conferences
August 26, 2021
Ironwood Pharmaceuticals Announces FDA Approval of Revised LINZESS® (linaclotide) Label
August 5, 2021
Ironwood Pharmaceuticals Reports Strong Second-Quarter 2021 Results, Raises Full-Year Guidance
August 3, 2021
Ironwood Pharmaceuticals Appoints John Minardo as Chief Legal Officer
July 22, 2021
Ironwood Pharmaceuticals to Host Second Quarter 2021 Investor Update Call
June 16, 2021
Ironwood Pharmaceuticals Announces That The American Journal of Gastroenterology Publishes Full Results from Positive LINZESS® (linaclotide) Phase IIIb Trial in Adults with Irritable Bowel Syndrome with Constipation (IBS-C)
June 7, 2021
Ironwood Pharmaceuticals Announces Leadership Updates
May 26, 2021
Ironwood Pharmaceuticals Announces Agreement with Teva Involving LINZESS® (linaclotide) 72 mcg Dosage Strength
May 24, 2021
More Than a Third of Surveyed IBS-C Patients Reported That Their Symptoms Worsened During COVID-19 According to New Survey Findings Presented by Ironwood Pharmaceuticals at Digestive Disease Week® (DDW)
May 17, 2021
Ironwood Pharmaceuticals to Present New Linaclotide Data and Unveil Findings From GI Disease Surveys at Digestive Disease Week® 2021
May 6, 2021
Ironwood Pharmaceuticals Announces New $150 Million Share Repurchase Program
May 6, 2021
Ironwood Pharmaceuticals Reports First Quarter 2021 Results
April 22, 2021
Ironwood Pharmaceuticals to Host First Quarter 2021 Investor Update Call
February 19, 2021
Ironwood Pharmaceuticals to Present at Upcoming Investor Conferences
February 17, 2021
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Results, Exceeding or Meeting Full Year 2020 Financial Guidance; Provides Full Year 2021 Financial Guidance
February 8, 2021
Ironwood Pharmaceuticals Announces CEO Transition
February 3, 2021
Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2020 Investor Update Call
January 5, 2021
Ironwood Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference